30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
A fusion of the EP400 (12q24) gene with the PHF1 gene is seen in ossifying fibromucinous tumors and is used as an aid to diagnosis. MEAF6-PHF1 and EPC1-PHF1 fusions are also seen in this tumor and can be detected with a PHF1 breakthrough probe (total positivity rate of 50%-80%). It may also be accompanied by a small number of ZC3H7B-BCOR, CREBBP-BCORL1 and KDM2A-WWTR1 fusions.
It is primarily distinguished from soft tissue myoepithelioma and extraosseous myxoid chondrosarcoma. Extraosseous myxoid chondrosarcoma is characterized by the t(9;22) translocation, forming the EWSR1-NR4A3 fusion gene (occurrence rate 50%–70%), as well as variant forms of NR4A3 fusions with other genes. NR4A3 breakpoint probes can be used to assist in diagnosis.